TRVI Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -- compared to Trevi Therapeutics's net margin of --. Trevi Therapeutics's return on equity of -- beat Perspective Therapeutics's return on equity of --.

Trevi Therapeutics has a consensus price target of $19.83, signalling upside risk potential of 225.14%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.39 which suggests that it could grow by 677.99%. Given that Perspective Therapeutics has higher upside potential than Trevi Therapeutics, analysts believe Perspective Therapeutics is more attractive than Trevi Therapeutics.

Trevi Therapeutics has a beta of 0.406, which suggesting that the stock is 59.351% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.199, suggesting its more volatile than the S&P 500 by 19.866%.

Trevi Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Trevi Therapeutics pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Trevi Therapeutics quarterly revenues are --, which are smaller than Perspective Therapeutics quarterly revenues of --. Trevi Therapeutics's net income of -$11.4M is higher than Perspective Therapeutics's net income of -$40.2M. Notably, Trevi Therapeutics's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Trevi Therapeutics is -- versus 11.98x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Checkpoint Therapeutics has a net margin of -- compared to Trevi Therapeutics's net margin of -16268.29%. Trevi Therapeutics's return on equity of -- beat Checkpoint Therapeutics's return on equity of --.

Trevi Therapeutics has a consensus price target of $19.83, signalling upside risk potential of 225.14%. On the other hand Checkpoint Therapeutics has an analysts' consensus of $4.33 which suggests that it could grow by 7.26%. Given that Trevi Therapeutics has higher upside potential than Checkpoint Therapeutics, analysts believe Trevi Therapeutics is more attractive than Checkpoint Therapeutics.

Trevi Therapeutics has a beta of 0.406, which suggesting that the stock is 59.351% less volatile than S&P 500. In comparison Checkpoint Therapeutics has a beta of 1.211, suggesting its more volatile than the S&P 500 by 21.135%.

Trevi Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Checkpoint Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Trevi Therapeutics pays -- of its earnings as a dividend. Checkpoint Therapeutics pays out -- of its earnings as a dividend.

Trevi Therapeutics quarterly revenues are --, which are smaller than Checkpoint Therapeutics quarterly revenues of $41K. Trevi Therapeutics's net income of -$11.4M is lower than Checkpoint Therapeutics's net income of -$9.7M. Notably, Trevi Therapeutics's price-to-earnings ratio is -- while Checkpoint Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Trevi Therapeutics is -- versus -- for Checkpoint Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Collegium Pharmaceutical has a net margin of -- compared to Trevi Therapeutics's net margin of 6.89%. Trevi Therapeutics's return on equity of -- beat Collegium Pharmaceutical's return on equity of 31.53%.

Trevi Therapeutics has a consensus price target of $19.83, signalling upside risk potential of 225.14%. On the other hand Collegium Pharmaceutical has an analysts' consensus of $42.80 which suggests that it could grow by 58.4%. Given that Trevi Therapeutics has higher upside potential than Collegium Pharmaceutical, analysts believe Trevi Therapeutics is more attractive than Collegium Pharmaceutical.

Trevi Therapeutics has a beta of 0.406, which suggesting that the stock is 59.351% less volatile than S&P 500. In comparison Collegium Pharmaceutical has a beta of 0.762, suggesting its less volatile than the S&P 500 by 23.775%.

Trevi Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Collegium Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Trevi Therapeutics pays -- of its earnings as a dividend. Collegium Pharmaceutical pays out -- of its earnings as a dividend.

Trevi Therapeutics quarterly revenues are --, which are smaller than Collegium Pharmaceutical quarterly revenues of $181.9M. Trevi Therapeutics's net income of -$11.4M is lower than Collegium Pharmaceutical's net income of $12.5M. Notably, Trevi Therapeutics's price-to-earnings ratio is -- while Collegium Pharmaceutical's PE ratio is 14.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Trevi Therapeutics is -- versus 1.74x for Collegium Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to Trevi Therapeutics's net margin of -49.65%. Trevi Therapeutics's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Trevi Therapeutics has a consensus price target of $19.83, signalling upside risk potential of 225.14%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 44.56%. Given that Trevi Therapeutics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Trevi Therapeutics is more attractive than NovaBay Pharmaceuticals.

Trevi Therapeutics has a beta of 0.406, which suggesting that the stock is 59.351% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.271%.

Trevi Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Trevi Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Trevi Therapeutics quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Trevi Therapeutics's net income of -$11.4M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Trevi Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Trevi Therapeutics is -- versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.